The Challenging Morbidity, Risk, and Therapeutic Continuum of MAC Lung Disease<br><sub>What Have We Learned from the ERS Treatment Guideline, Real World Experience, and Recent Trials Focused on High Risk/Refractory MAC Lung Disease?</sub>

The Challenging Morbidity, Risk, and Therapeutic Continuum of MAC Lung Disease
What Have We Learned from the ERS Treatment Guideline, Real World Experience, and Recent Trials Focused on High Risk/Refractory MAC Lung Disease?


Published

August 31, 2022

Created by

CMEducation Resources symposium

Related Presenters

Christoph Lange, MD

Christoph Lange, MD

Medical Director/Clinical Director
Research Center Borstel
Borstel, Germany